^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Cervical Cancer
    Drug:Aybintio (bevacizumab biosimilar) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Samsung
    Title:

    Samsung Bioepis acquires European sales license for anticancer drug'Abincio (SB8)'

    Published date:
    08/21/2020
    Excerpt:
    Samsung Bioepis (CEO: Han-Seung Ko) from the European Commission (EC) It was announced on the 21st that it has obtained the final marketing approval for'AYBINTIO ® , Avastin biosimilar, project name SB8, ingredient name bevacizumab' in Europe.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix...
    Secondary therapy:
    cisplatin + paclitaxel; paclitaxel + topotecan